Two Zolgensma patients die of liver failure
On August 11, 2022, Novartis reported the death of two Zolgensma patients from liver failure. Zolgensma (onasemnogene abeparvovec), produced by AveXis, a Novartis company, is a gene therapy medicine, containing the active ingredient onasemnogene abeparvovec. Zolgensma has been used for the treatment of pediatric patients with … [Read more...]
Novartis Uses Manipulated Data to Gain Zolgensma’s FDA Approval
UNITED STATES – According to an online news article published by www.the-scientist.com, the FDA is investigating Novartis after learning that the company submitted its application for Zolgensma, a gene therapy drug, with manipulated data. Novartis Pharmaceuticals gained United States Food and Drug Administration (FDA) approval of … [Read more...]
Manipulated Data to Gain FDA Approval of Zolgensma
Novartis Pharmaceuticals Used Manipulated Data to Gain FDA Approval of Gene Therapy Drug Novartis Pharmaceuticals, a global drug company, recently revealed that the company submitted an application to the United States Food and Drug Administration (FDA) for approval of Zolgensma, a gene therapy drug, with manipulated data. The … [Read more...]
